Navigation Links
MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
Date:11/13/2013

WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death.  MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.  MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma.

This invention addresses the need to direct the powerful biological effect of miRNAs such as MCT-485 towards tumor cells and away from normal tissues.  This patent application describes compositions and methods that target populations of cancerous cells which have an enhanced capability to mediate the process of relapse, progression and metastasis.  Not all cancer cells have a tumor initiating capability; this U.S. patent application describes compositions and methods that target cancer by delivering a biologically active, cytotoxic payload of miRNA to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells, and to kill those cells without killing cells not directly involved in the process of relapse, progression and metastasis of cancer.

Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death worldwide.  Over 1 million cases of hepatocellular carcinoma are reported annually.  Current approaches for treatment of hepatocellular carcinoma are of limited efficacy.  MCT-485, possessing both oncolytic and immune activating properties, could be superior to doxorubicin, cisplatin and other currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect.

About MCT-485

MultiCell Technologies' MCT-485 is a noncoding double stranded micro RNA (miRNA), and the first of a family of prospective cancer therapeutics.  MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485 and other miRNAs.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2012, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer
2. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
3. Life Technologies Announces Third Quarter 2013 Results
4. Bend Research to Highlight Latest Drug Formulation Technologies
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2013 Financial Results on Tuesday, November 12, 2013
6. BioStorage Technologies Selected to Provide Technical Consulting to Chinese National Genebank
7. Adaptive Biotechnologies Publishes Gold Standard Method for Sequencing Cells of the Adaptive Immune System
8. BCC Research Publishes a New Report On Global Markets for Rnai Technologies
9. Forensic Technologies and Services - 2013 Global Strategic Business Report
10. Modality Solutions Releases New White Paper on Thermal Shipping Technologies
11. NPI Volunteers Carry ‘Essential Technologies’ Message to Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) ... Monitoring Board (DSMB) for the Company,s Phase 3 ... has completed a second planned safety review and ... without any modifications. The DSMB reviewed available study ... concerns were identified. The DSMB will conduct additional ...
(Date:12/5/2016)... Research and Markets has announced the ... Technologies, Markets and Companies" to their offering. ... , , ... human genome variations, development of sequencing technologies, and their applications. ... companies developing them. Various applications of sequencing are described including ...
(Date:12/4/2016)... San Francisco, CA (PRWEB) , ... December 03, ... ... scientific grants to ground-breaking microbiome studies. A microbiome impact grant award has been ... study the effect of heavy smoking and drinking on the oral microbiome. Grant ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s ... disc production, company President, Jake Lubinski will be traveling to Switzerland from December ... in Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):